How to use monoclonal antibody-based therapy in ALL
Acute Lymphoblastic Leukemia (ALL) represents a significant challenge in haematology, particularly due to its aggressive nature, high relapse rates in adults and toxicity of treatment. Over the past decade, monoclonal antibody (MoAb)-based therapies have emerged as a promising approach to target spe...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | EJC Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772610X25000017 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591753611313152 |
|---|---|
| author | Erica Brivio Sujith Samarasinghe |
| author_facet | Erica Brivio Sujith Samarasinghe |
| author_sort | Erica Brivio |
| collection | DOAJ |
| description | Acute Lymphoblastic Leukemia (ALL) represents a significant challenge in haematology, particularly due to its aggressive nature, high relapse rates in adults and toxicity of treatment. Over the past decade, monoclonal antibody (MoAb)-based therapies have emerged as a promising approach to target specific antigens on leukemic cells, offering higher specificity, reduced toxicity, and improved response rates. This article provides an in-depth examination of the journey from laboratory research to clinical application, discussing mechanisms of action, key MoAbs used in ALL, their clinical applications, current challenges, and potential future directions in antibody-based therapy. |
| format | Article |
| id | doaj-art-273ef6ff05934b09840293f4aea339c4 |
| institution | Kabale University |
| issn | 2772-610X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EJC Paediatric Oncology |
| spelling | doaj-art-273ef6ff05934b09840293f4aea339c42025-01-22T05:44:26ZengElsevierEJC Paediatric Oncology2772-610X2025-06-015100214How to use monoclonal antibody-based therapy in ALLErica Brivio0Sujith Samarasinghe1Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Correspondence to: Princess Máxima Center for Pediatric Oncology and Dept. of Pediatric Oncology Erasmus MC-Sophia Children’s Hospital, Utrecht, the Netherlands.Great Ormond Street Hospital for Children NHS Foundation Trust, London, United KingdomAcute Lymphoblastic Leukemia (ALL) represents a significant challenge in haematology, particularly due to its aggressive nature, high relapse rates in adults and toxicity of treatment. Over the past decade, monoclonal antibody (MoAb)-based therapies have emerged as a promising approach to target specific antigens on leukemic cells, offering higher specificity, reduced toxicity, and improved response rates. This article provides an in-depth examination of the journey from laboratory research to clinical application, discussing mechanisms of action, key MoAbs used in ALL, their clinical applications, current challenges, and potential future directions in antibody-based therapy.http://www.sciencedirect.com/science/article/pii/S2772610X25000017Pediatric leukemiaALLMonoclonal antibodies |
| spellingShingle | Erica Brivio Sujith Samarasinghe How to use monoclonal antibody-based therapy in ALL EJC Paediatric Oncology Pediatric leukemia ALL Monoclonal antibodies |
| title | How to use monoclonal antibody-based therapy in ALL |
| title_full | How to use monoclonal antibody-based therapy in ALL |
| title_fullStr | How to use monoclonal antibody-based therapy in ALL |
| title_full_unstemmed | How to use monoclonal antibody-based therapy in ALL |
| title_short | How to use monoclonal antibody-based therapy in ALL |
| title_sort | how to use monoclonal antibody based therapy in all |
| topic | Pediatric leukemia ALL Monoclonal antibodies |
| url | http://www.sciencedirect.com/science/article/pii/S2772610X25000017 |
| work_keys_str_mv | AT ericabrivio howtousemonoclonalantibodybasedtherapyinall AT sujithsamarasinghe howtousemonoclonalantibodybasedtherapyinall |